Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2022-08-02 Director's Dealing
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Form 4 - Michael Rabinowitz
Director's Dealing Classification · 98% confidence The document explicitly mentions 'Form 4 - Michael Rabinowitz' attached as a PDF, and the content details a signatory (Chief Legal Officer & Secretary) reporting on a transaction. Form 4 filings in the US context (and often mirrored in international filings referencing US standards) relate to insider transactions by directors or principal officers. This directly corresponds to the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document is a notification/report itself, not an announcement of a report, and it is highly specific, ruling out general categories like RNS or RPA.
2022-08-02 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Form 4 - Leonard Sank
Director's Dealing Classification · 100% confidence The document explicitly begins with '# **FORM 4**' and is titled 'STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES' filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. Form 4 filings are used by corporate insiders (directors, officers, or 10% owners) to report transactions in the company's securities. This directly corresponds to the definition of Director's Dealing (insider trades). Reviewing the provided definitions, 'Director's Dealing (Code: DIRS)' is defined as 'Report of personal share transactions by company directors and executives (insider trades)'. This is the precise classification for a Form 4 filing.
2022-08-02 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Form 4 - Leonard Sank
Director's Dealing Classification · 99% confidence The document explicitly states it is reporting under 'Regulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation)' and attaches a document titled '*Form 4 - Leonard Sank*'. Form 4 filings in the US context (and implied here by the NASDAQ listing and US address) are used to report insider transactions, specifically changes in beneficial ownership by directors, officers, or principal stockholders. This directly corresponds to the definition of Director's Dealing (insider trades). The filing type code for Director's Dealing is DIRS.
2022-08-02 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Hexter Joshua
Director's Dealing Classification · 99% confidence The document explicitly begins with '# **FORM 4**' and is titled 'STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES', filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. This form is used by corporate insiders (directors, officers, or 10% owners) to report transactions in the company's securities. Among the provided classification codes, 'Director's Dealing' (DIRS) is the most appropriate category for reporting personal share transactions by company directors and executives (insider trades), as Form 4 is the standard SEC filing for this purpose.
2022-08-02 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Hexter Joshua
Director's Dealing Classification · 99% confidence The document explicitly states it is an 'Other Report or Announcement' under Israeli regulations and attaches a document titled '*Form 4 - Joshua Hexter*'. Form 4 is the standard SEC filing used to report insider transactions (changes in beneficial ownership) by directors, officers, or 10% shareholders. This directly corresponds to the definition of Director's Dealing (insider trades). The filing type code for Director's Dealing is DIRS.
2022-08-02 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Form 4 - David Silberman
Director's Dealing Classification · 100% confidence The document explicitly begins with "FORM 4" and contains the header "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934". Form 4 filings are used by corporate insiders (directors, officers, or 10% owners) to report transactions in the company's securities. This directly corresponds to the definition of Director's Dealing (insider trades). Although the provided definitions do not explicitly list 'Form 4', the content (reporting personal share transactions by directors/executives) perfectly matches the description for 'Director's Dealing' (Code: DIRS).
2022-08-02 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.